Although high-sensitivity troponin I (hsTnI) plasma levels are not mentioned in current guideline recommendations, combined measure of BNP and hsTnI have been recognized as predictors of adverse outcomes in LFLG-AS patients (7–9). This evidence concerns the gene NPPB and aortic stenosis.